CGTLive®’s Weekly Rewind – April 26, 2024

News
Article

Review top news and interview highlights from the week ending April 26, 2024.

CGTLive®’s Weekly Rewind – April 26, 2024

CGTLive®’s Weekly Rewind – April 26, 2024

Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. FDA Issues CRL for Abeona's Epidermolysis Bullosa Gene Therapy Pz-Cel

The FDA is requesting more CMC information, specifically with regard to validation requirements for specific manufacturing and release testing methods.

2. Akshay Sharma, MBBS, on Overcoming Challenges for Administration of Ex-Vivo SCD Gene Therapy

The attending physician and assistant member of bone marrow transplantation and cellular therapy at St Jude Children’s Research Hospital also discussed hurdles to accessibility for SCD gene therapy.

3. One Big Step Away From BLA Submission for Sangamo’s Fabry Gene Therapy

The FDA is allowing a small, single-arm study to support a BLA submission of ST-290, if Sangamo can find help to continue developing the therapy.

4. Alexandra Gomez-Arteaga, MD, on Expanding Eligibility for Cell Transplant With Cell Therapy

The Assistant Professor of Medicine at Weill Cornell Medical College discussed the changing cell transplant landscape.

5. First Patient Treated With Benitec Biopharma’s Oculopharyngeal Muscular Dystrophy Gene Therapy Shows Swallowing Improvements

At the 90 day timepoint, the patient showed improvements in swallowing compared to their own natural history data, as measured by videofluoroscopic swallowing studies.

Recent Videos
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Sarah Larson, MD, the medical director of the Immune Effector Cell Therapy Program in the Division of Hematology/Oncology at David Geffen School of Medicine at University of California, Los Angeles (UCLA)
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.